MedPath

A phase I trial of biweekly nab-paclitaxel plus ramucirumab in patients with previously treated advanced gastric cancer

Phase 1
Conditions
metastatic or recurrent gastric cancer
Registration Number
JPRN-UMIN000021949
Lead Sponsor
Tokushima University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

1)patient with allergy of paclitaxel or ramucirumab 2)patient with contraindication for paclitaxel or ramucirumab 3)patient who had previously administered with paclitaxel as first line therapy 4)patient who has a serious infection 5)patient who has serious complications such as heart disease, respitary disorder, cerebrovascular disorder, liver disease and much ascites or pleural effusion 6)patient who has recieved chemotherapy within 2weeks 7)patient who has recieved therapy with blood products 8)patient with other malignat tumor 9)patient with neuropathy (>=grade 2) 10)patient with urinary protein (>=grade 2) 11)patient with brain symptomatic metastasis 12)patient who recieved with steroid 13)patient with psychic disorder 14)patient with pregnancy, lactating or possibility of pregnancy 15)patient who given a dicision of unsuitable for this study by the investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath